{
  "trial_id": "NCT03516812",
  "trial_group": "cancer",
  "generated-by-gpt4-omni-zs": {
    "gen-response": "Age, sex, race, baseline PSA level, ECOG performance status, hemoglobin level, absolute neutrophil count, platelet count, total bilirubin level, AST level, ALT level, creatinine clearance, prior treatments (abiraterone, enzalutamide, docetaxel), presence of metastases, DNA damage response (DDR) gene status, life expectancy, use of contraception, compliance with protocol, presence of measurable lesions, availability of archival tissue or ctDNA, history of other malignancies, ECG findings, use of CYP3A inhibitors or inducers, presence of toxicities from previous therapies, history of myelodysplastic syndrome/acute myeloid leukemia, brain metastases status, history of major surgery, presence of serious medical conditions, ability to swallow medication, immunocompromised status, hypersensitivity to study drugs, hepatitis status, history of bone marrow transplant, history of blood transfusions, psychological or familial conditions, risk from testosterone therapy, presence of pain, urinary outlet obstruction status, history of deep venous thrombosis or pulmonary embolism, NYHA class heart failure, history of myocardial infarction.",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Male",
          "sex"
        ],
        [
          "PSA",
          "baseline PSA level"
        ],
        [
          "Prior abiraterone treatment",
          "prior treatments (abiraterone, enzalutamide, docetaxel)"
        ],
        [
          "Prior enzalutamide treatment",
          "prior treatments (abiraterone, enzalutamide, docetaxel)"
        ],
        [
          "Prior docetaxel treatment",
          "prior treatments (abiraterone, enzalutamide, docetaxel)"
        ]
      ],
      "remaining_reference_features": [
        "Sex: Female",
        "Race (NIH/OMB)"
      ],
      "remaining_candidate_features": [
        "race",
        "ECOG performance status",
        "hemoglobin level",
        "absolute neutrophil count",
        "platelet count",
        "total bilirubin level",
        "AST level",
        "ALT level",
        "creatinine clearance",
        "presence of metastases",
        "DNA damage response (DDR) gene status",
        "life expectancy",
        "use of contraception",
        "compliance with protocol",
        "presence of measurable lesions",
        "availability of archival tissue or ctDNA",
        "history of other malignancies",
        "ECG findings",
        "use of CYP3A inhibitors or inducers",
        "presence of toxicities from previous therapies",
        "history of myelodysplastic syndrome/acute myeloid leukemia",
        "brain metastases status",
        "history of major surgery",
        "presence of serious medical conditions",
        "ability to swallow medication",
        "immunocompromised status",
        "hypersensitivity to study drugs",
        "hepatitis status",
        "history of bone marrow transplant",
        "history of blood transfusions",
        "psychological or familial conditions",
        "risk from testosterone therapy",
        "presence of pain",
        "urinary outlet obstruction status",
        "history of deep venous thrombosis or pulmonary embolism",
        "NYHA class heart failure",
        "history of myocardial infarction"
      ]
    },
    "processed-gen-response": "Age, sex, race, baseline PSA level, ECOG performance status, hemoglobin level, absolute neutrophil count, platelet count, total bilirubin level, AST level, ALT level, creatinine clearance, prior treatments (abiraterone, enzalutamide, docetaxel), presence of metastases, DNA damage response (DDR) gene status, life expectancy, use of contraception, compliance with protocol, presence of measurable lesions, availability of archival tissue or ctDNA, history of other malignancies, ECG findings, use of CYP3A inhibitors or inducers, presence of toxicities from previous therapies, history of myelodysplastic syndrome/acute myeloid leukemia, brain metastases status, history of major surgery, presence of serious medical conditions, ability to swallow medication, immunocompromised status, hypersensitivity to study drugs, hepatitis status, history of bone marrow transplant, history of blood transfusions, psychological or familial conditions, risk from testosterone therapy, presence of pain, urinary outlet obstruction status, history of deep venous thrombosis or pulmonary embolism, NYHA class heart failure, history of myocardial infarction."
  },
  "generated-by-gpt4-omni-ts": {
    "gen-response": "Age, Continuous, Sex: Male, Race/Ethnicity, Customized, Region of Enrollment, Baseline PSA level, Hemoglobin, Absolute Neutrophil Count (ANC), Platelet count, Total bilirubin, Aspartate aminotransferase (AST), Alanine aminotransferase (ALT), Creatinine clearance, Eastern Cooperative Oncology Group (ECOG) performance status, Life expectancy, DNA damage response (DDR) gene status,",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Male",
          "Sex: Male"
        ],
        [
          "PSA",
          "Baseline PSA level"
        ],
        [
          "Prior abiraterone treatment",
          "Prior abiraterone treatment"
        ],
        [
          "Prior enzalutamide treatment",
          "Prior enzalutamide treatment"
        ],
        [
          "Prior docetaxel treatment",
          "Prior docetaxel treatment"
        ]
      ],
      "remaining_reference_features": [
        "Sex: Female",
        "Race (NIH/OMB)"
      ],
      "remaining_candidate_features": [
        "Race/Ethnicity",
        "Region of Enrollment",
        "Hemoglobin",
        "Absolute Neutrophil Count (ANC)",
        "Platelet count",
        "Total bilirubin",
        "Aspartate aminotransferase (AST)",
        "Alanine aminotransferase (ALT)",
        "Creatinine clearance",
        "Eastern Cooperative Oncology Group (ECOG) performance status",
        "Life expectancy",
        "DNA damage response (DDR) gene status"
      ]
    },
    "processed-gen-response": "Age, Sex: Male, Race/Ethnicity, Region of Enrollment, Baseline PSA level, Hemoglobin, Absolute Neutrophil Count (ANC), Platelet count, Total bilirubin, Aspartate aminotransferase (AST), Alanine aminotransferase (ALT), Creatinine clearance, Eastern Cooperative Oncology Group (ECOG) performance status, Life expectancy, DNA damage response (DDR) gene status"
  },
  "generated-by-llama3-70b-in-ts": {
    "gen-response": "Age, Continuous, Sex: Male, Race/Ethnicity, Customized, Region of Enrollment, ECOG Performance Status, PSA at Baseline, Gleason Score, Prior Treatment with Abiraterone and/or Enzalutamide, Prior Chemotherapy for Hormone-Sensitive Prostate Cancer, Hemoglobin, Absolute Neutrophil Count, Platelet Count, Total Bilirubin, AST, ALT, Creatinine Clearance.",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Male",
          "Sex: Male"
        ],
        [
          "PSA",
          "PSA at Baseline"
        ],
        [
          "Prior abiraterone treatment",
          "Prior Treatment with Abiraterone and/or Enzalutamide"
        ],
        [
          "Prior enzalutamide treatment",
          "Prior Treatment with Abiraterone and/or Enzalutamide"
        ],
        [
          "Prior docetaxel treatment",
          "Prior Chemotherapy for Hormone-Sensitive Prostate Cancer"
        ]
      ],
      "remaining_reference_features": [
        "Sex: Female",
        "Race (NIH/OMB)"
      ],
      "remaining_candidate_features": [
        "Race/Ethnicity",
        "Region of Enrollment",
        "ECOG Performance Status",
        "Gleason Score",
        "Hemoglobin",
        "Absolute Neutrophil Count",
        "Platelet Count",
        "Total Bilirubin",
        "AST",
        "ALT",
        "Creatinine Clearance"
      ]
    },
    "processed-gen-response": "Age, Sex: Male, Race/Ethnicity, Region of Enrollment, ECOG Performance Status, PSA at Baseline, Gleason Score, Prior Treatment with Abiraterone and/or Enzalutamide, Prior Chemotherapy for Hormone-Sensitive Prostate Cancer, Hemoglobin, Absolute Neutrophil Count, Platelet Count, Total Bilirubin, AST, ALT, Creatinine Clearance."
  },
  "generated-by-llama3-70b-in-zs": {
    "gen-response": "Age, race, ethnicity, ECOG performance status, PSA at baseline, Gleason score, prior treatment with abiraterone and/or enzalutamide, prior chemotherapy for hormone-sensitive prostate cancer, presence of metastases, hemoglobin, absolute neutrophil count, platelet count, total bilirubin, AST, ALT, creatinine clearance, life expectancy.",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Race (NIH/OMB)",
          "race"
        ],
        [
          "PSA",
          "PSA at baseline"
        ],
        [
          "Prior abiraterone treatment",
          "prior treatment with abiraterone and/or enzalutamide"
        ],
        [
          "Prior enzalutamide treatment",
          "prior treatment with abiraterone and/or enzalutamide"
        ],
        [
          "Prior docetaxel treatment",
          "prior chemotherapy for hormone-sensitive prostate cancer"
        ]
      ],
      "remaining_reference_features": [
        "Sex: Female",
        "Male"
      ],
      "remaining_candidate_features": [
        "ethnicity",
        "ECOG performance status",
        "Gleason score",
        "presence of metastases",
        "hemoglobin",
        "absolute neutrophil count",
        "platelet count",
        "total bilirubin",
        "AST",
        "ALT",
        "creatinine clearance",
        "life expectancy."
      ]
    },
    "processed-gen-response": "Age, race, ethnicity, ECOG performance status, PSA at baseline, Gleason score, prior treatment with abiraterone and/or enzalutamide, prior chemotherapy for hormone-sensitive prostate cancer, presence of metastases, hemoglobin, absolute neutrophil count, platelet count, total bilirubin, AST, ALT, creatinine clearance, life expectancy."
  }
}